Prestige BioPharma Limited Stock: price and insider trades · South Korea
프레스티지바이오파마
1 insider bought shares over the last 90 days, the latest by 고상석, filed 01 Sept 2026.
Prestige BioPharma Limited: what insiders have been doing
This page follows insider dealings at Prestige BioPharma Limited as filed with DART (FSS), a company from the Health Care sector. From 22 October 2025 to 22 October 2026, the disclosure feed for Prestige BioPharma Limited logged 9 filings by 4 insiders.
Only purchases show up on the open market, 9 purchases in all worth €42k, filed by 4 insiders. The amount is not disclosed for 7 filings. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Biggest ticket of the year: €35k, bought by 김 마이클 진우 and made public on 1 July 2026. Those buying include 1 major shareholder and 1 chief executive.
The last insider purchase was made public on 1 September 2026, 70 days ago.
Compared with its exchange (2,650 companies, median 7 filings), a count of 9 filings is above the norm. Our records for Prestige BioPharma Limited go back to 2021, with 24 purchases and no sales on the open market in total.
Other companies in the same sector with recent insider buying flagged by our signals: Xenon Pharmaceuticals Inc. and Vivos Inc. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- -4.9%Entry ₩5,760 · Close 20 Oct 2026 ₩5,480
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended June 2025 · cache
- 4,800 sharesShareKRXDART:20260901000026Canonical exit: 30 Nov 2026 (T+90)
- Other0DART
- 4,320 sharesShareKRXDART:20260819000125Canonical exit: 17 Nov 2026 (T+90)
- Other0DART
- 10,347 sharesShareKRXDART:20260811000034Canonical exit: 9 Nov 2026 (T+90)
- Other0DART
- 14,000 sharesShareKRXDART:20260804000107Canonical exit: 2 Nov 2026 (T+90)
- 18,353 sharesShareKRXDART:20260804000527Canonical exit: 2 Nov 2026 (T+90)
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- 2,000 shares@ ₩6,252.0016.9% of flowShareKRXDART:20260709000564Canonical exit: 30 Sept 2026 (T+90)
- 2,000 sharesKRXDART:20260709000557Canonical exit: 7 Oct 2026 (T+90)
- 9,900 shares@ ₩6,190.89983.1% of flowShareKRXDART:20260701000188Canonical exit: 23 Sept 2026 (T+90)
- 9,900 sharesKRXDART:20260701000259Canonical exit: 29 Sept 2026 (T+90)
- ●Executives0DART
- ShareKRXDART:20241004000029Canonical exit: 26 Dec 2024 (T+90)
- 0KRXDART:20231215000431
- ShareKRXDART:20230721000603Canonical exit: 19 Oct 2023 (T+90)
- 0KRXDART:20230721000593
- 400 sharesKRXDART:20230306000367Canonical exit: 4 Jun 2023 (T+90)
25 of 58 declarations
About Prestige BioPharma Limited
Prestige Biopharma is a company specializing in the health and pharmaceutical sector, listed on the XKRX market. It focuses on the development of innovative biologic drugs.
